Decoy Appoints Renowned MIT Professor to Advisory Board Amid Merger with Salarius

Decoy Therapeutics, a preclinical biopharmaceutical company specializing in peptide-conjugate therapeutics, has announced the prestigious addition of Robert S. Langer, a renowned MIT professor and co-founder of Moderna, to its Scientific Advisory Board. This announcement coincides with an impending merger between Decoy and Salarius Pharmaceuticals. The merger aims to enhance the development of Decoy's innovative antiviral and cancer therapies. Dr. Langer's extensive experience in drug delivery systems, coupled with his groundbreaking contributions to biotechnology, is expected to significantly benefit Decoy's proprietary IMP3ACT platform. As per the merger agreement, Decoy investors will own a substantial share post-merger, with Decoy becoming a subsidiary of Salarius. The collaboration poises to revolutionize therapeutic drug development with its focus on peptide conjugates, which have shown potent activity against various diseases. This strategic move not only consolidates Decoy's research capabilities but also promises expanded pipelines for groundbreaking drug delivery solutions.